Literature DB >> 17695480

Dummy run for a phase II multi-institute trial of chemoradiotherapy for unresectable pancreatic cancer: inter-observer variance in contour delineation.

Hideya Yamazaki1, Kinji Nishiyama, Eiichi Tanaka, Keiichiro Koiwai, Naoto Shikama, Yoshinori Ito, Satoko Arahira, Tetsuro Tamamoto, Toru Shibata, Yoshio Tamaki, Takeshi Kodaira, Masahiko Oguchi.   

Abstract

UNLABELLED: The aim of this study was to examine the interobserver variance in delineating the contour of unresectable pancreatic cancer for chemoradiotherapy. PATIENTS AND METHODS: CT images of two cases of unresectable pancreatic tumors (head and body cancer) were sent to eight radiation therapy facilities in a CD-ROM. Gross tumor volume (GTV) and planning target volume (PTV) were delineated using the radiotherapy treatment planning system (RTP) of the respective facilities. The mean and variance of the GTV and PTV of 11 plans by the eight facilities were analyzed.
RESULTS: The respective mean volumes of the GTV of pancreatic head and body cancer cases were 34.8 cm3 (SD, 30.4; median, 31.8; range, 13.5-122 cm3) and 73.4 cm3 (SD, 28.1; median, 67.9; range, 46.3-152 cm3). The ratios of the largest to the smallest contoured GTV were 9 and 3, respectively. The corresponding average volumes of PTV were 148 cm3 (SD, 84.3; median, 129; range, 69.6-363 cm3) and 240 cm3 (SD, 79.8; median, 227; range, 148-420 cm3). The ratios of the largest to the smallest contoured volume were 5 and 2.8 for PTV delineation, respectively.
CONCLUSION: Dummy run using CD-ROM is possible on a multi-institute scale but also disclosed interobserver variance. Unified protocol interpretation to reduce inter-observer variance is therefore essential for successful multi-institute clinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17695480

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Development of a software for quantitative evaluation radiotherapy target and organ-at-risk segmentation comparison.

Authors:  Jayashree Kalpathy-Cramer; Musaddiq Awan; Steven Bedrick; Coen R N Rasch; David I Rosenthal; Clifton D Fuller
Journal:  J Digit Imaging       Date:  2014-02       Impact factor: 4.056

2.  Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting.

Authors:  Clifton D Fuller; Jasper Nijkamp; Joop C Duppen; Coen R N Rasch; Charles R Thomas; Samuel J Wang; Paul Okunieff; William E Jones; Daniel Baseman; Shilpen Patel; Carlo G N Demandante; Anna M Harris; Benjamin D Smith; Alan W Katz; Camille McGann; Jennifer L Harper; Daniel T Chang; Stephen Smalley; David T Marshall; Karyn A Goodman; Niko Papanikolaou; Lisa A Kachnic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-18       Impact factor: 7.038

3.  General and custom deep learning autosegmentation models for organs in head and neck, abdomen, and male pelvis.

Authors:  Asma Amjad; Jiaofeng Xu; Dan Thill; Colleen Lawton; William Hall; Musaddiq J Awan; Monica Shukla; Beth A Erickson; X Allen Li
Journal:  Med Phys       Date:  2022-02-07       Impact factor: 4.071

4.  Clinical target volume delineation including elective nodal irradiation in preoperative and definitive radiotherapy of pancreatic cancer.

Authors:  Luciana Caravatta; Giuseppina Sallustio; Fabio Pacelli; Gilbert D A Padula; Francesco Deodato; Gabriella Macchia; Mariangela Massaccesi; Vincenzo Picardi; Savino Cilla; Alfonso Marinelli; Numa Cellini; Vincenzo Valentini; Alessio G Morganti
Journal:  Radiat Oncol       Date:  2012-06-12       Impact factor: 3.481

5.  Quantitative assessment of inter-observer variability in target volume delineation on stereotactic radiotherapy treatment for pituitary adenoma and meningioma near optic tract.

Authors:  Hideya Yamazaki; Hiroya Shiomi; Takuji Tsubokura; Naohiro Kodani; Takuya Nishimura; Norihiro Aibe; Hiroki Udono; Manabu Nishikata; Yoshimi Baba; Mikio Ogita; Koichi Yamashita; Tadayuki Kotsuma
Journal:  Radiat Oncol       Date:  2011-01-27       Impact factor: 3.481

6.  Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case.

Authors:  Francesca Lobefalo; Mario Bignardi; Giacomo Reggiori; Angelo Tozzi; Stefano Tomatis; Filippo Alongi; Antonella Fogliata; Anna Gaudino; Piera Navarria; Luca Cozzi; Marta Scorsetti; Pietro Mancosu
Journal:  Radiat Oncol       Date:  2013-07-09       Impact factor: 3.481

7.  Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run.

Authors:  Eva Versteijne; Eelco Lens; Astrid van der Horst; Arjan Bel; Jorrit Visser; Cornelis J A Punt; Mustafa Suker; Casper H J van Eijck; Geertjan van Tienhoven
Journal:  Strahlenther Onkol       Date:  2017-06-12       Impact factor: 3.621

8.  Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study.

Authors:  Eva Versteijne; Oliver J Gurney-Champion; Astrid van der Horst; Eelco Lens; M Willemijn Kolff; Jeroen Buijsen; Gati Ebrahimi; Karen J Neelis; Coen R N Rasch; Jaap Stoker; Marcel van Herk; Arjan Bel; Geertjan van Tienhoven
Journal:  Radiat Oncol       Date:  2017-03-23       Impact factor: 3.481

9.  Inter-observer variability of clinical target volume delineation in radiotherapy treatment of pancreatic cancer: a multi-institutional contouring experience.

Authors:  Luciana Caravatta; Gabriella Macchia; Gian Carlo Mattiucci; Aldo Sainato; Nunzia L V Cernusco; Giovanna Mantello; Monica Di Tommaso; Marianna Trignani; Antonino De Paoli; Gianni Boz; Maria L Friso; Vincenzo Fusco; Marta Di Nicola; Alessio G Morganti; Domenico Genovesi
Journal:  Radiat Oncol       Date:  2014-09-08       Impact factor: 3.481

10.  Dosimetric effects of anatomical changes during fractionated photon radiation therapy in pancreatic cancer patients.

Authors:  Astrid van der Horst; Antonetta C Houweling; Geertjan van Tienhoven; Jorrit Visser; Arjan Bel
Journal:  J Appl Clin Med Phys       Date:  2017-10-04       Impact factor: 2.102

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.